Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...

The bacillus Calmette–Guérin (BCG) vaccine, initially developed to provide protection against TB, also protects against leprosy; and the magnitude of this effect varies. Previous meta-analyses ...

Intravesical cretostimogene continues to show durable response for up to 22 months in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Cretostimogene ...